Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Seres Therapeutics Inc (MCRB)

35 + Investors. Track Smart Money conviction in MCRB. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +2
Streak
1Q ▲
Buyers last Q
47%

Smart Money Signals — MCRB

Based on 35 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added MCRB than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
📊

High ownership — 92% of 3.0Y peak

92% of all-time peak
35 funds currently hold this stock — 92% of the 3.0-year high of 38 funds (reached 2025 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding MCRB is almost the same as a year ago (+1 funds, +3% change). No significant rush to buy or sell — institutional backing is holding steady.
🟠

More sellers than buyers — 47% buying

16 buying18 selling
Last quarter: 18 funds reduced or exited vs 16 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~8 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 14 → 8 → 5 → 8. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔄

Mostly new holders — 40% entered in last year

■ 6% conviction (2yr+) ■ 54% medium ■ 40% new
Only 2 funds (6%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
⚠️

Saturation — most institutions already know this story

33 → 14 → 8 → 5 → 8 new funds/Q
New funds entering each quarter: 14 → 8 → 5 → 8. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.
🌱

Early stage — 97% of holders entered in last year

■ 0% veterans ■ 3% 1-2yr ■ 97% new
Of 38 current holders: 37 (97%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
📋

Smaller funds dominant — 16% AUM from top-100

16% from top-100 AUM funds
17 of 35 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MCRB

In 2026 Q2, 16 hedge funds were net buyers of MCRB (8 opened a new position, 8 added to an existing one), while 18 reduced or exited (12 trimmed, 6 sold completely) — a 47% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: +2 funds (more new holders than closures). Total institutional holders: 35.

Hedge Fund Ownership: MCRB

How many hedge funds hold MCRB — quarterly history vs. share price
Quarterly hedge fund ownership of MCRB vs. share price

Market Analysis: MCRB

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MCRB

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Seres Therapeutics Inc (MCRB) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MCRB has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 60d ago
MCRB
-37.3%
XLV
+8.1%

MCRB outperformed XLV by -45.4% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 15d ago
MCRB
+9.0%
XLV
+2.5%

Since the filing became public, MCRB outperformed XLV by +6.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

3 top-rated funds 0 high-conviction
Consensus
2.6
/ 10
breadth
×
Elite
0.5
/ 10
conviction
Hedge Fund Positioning: MCRB
35 + Investors

Track Smart Money conviction in MCRB. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 35 33 6.06%
13F Shares 2M 2M -3.81%
Total Value $19M $22M -14.44%
New Positions 8 5 +3
Increased Positions 7 9 -2
Closed Positions 6 9 -3
Reduced Positions 12 9 +3
Total Calls 1 1 -
Total Puts 2 2 -
PUT/CALL Ratio 2.0 2.0 Bearish

Statistics: MCRB

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

35 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MCRB. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MCRB holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Lion Point Capital, LP 1.19% 31,570 $249K
2 Flagship Pioneering, LLC 0.59% 1,155,850 $9.1M
3 Rachor Investment Advisory Services, LLC 0.01% 1,477 $12K
4 Vontobel Holding Ltd. 0.00% 122,975 $970K
5 XTX Topco Ltd 0.00% 20,732 $164K
6 Marshall Wace, LLP 0.00% 172,245 $1.4M
7 SBI Securities Co., Ltd. 0.00% 4,182 $33K
8 Integrated Wealth Concepts LLC 0.00% 4,000 $32K
9 American Century Companies Inc 0.00% 28,313 $223K
10 Vanguard Fiduciary Trust Co 0.00% 48,685 $384K
11 Tower Research Capital LLC (TRC) 0.00% 316 $2K
12 Vanguard Capital Management LLC 0.00% 287,776 $2.3M
13 Group One Trading LLC 0.00% 3,714 $29K
14 Citadel Advisors LLC 0.00% 43,500 $343K
15 Susquehanna International Group, LLP 0.00% 63,800 $503K
16 Susquehanna International Group, LLP 0.00% 58,328 $460K
17 Continuum Advisory, LLC 0.00% 47 —
18 Simplex Trading, LLC 0.00% 4,598 $36K
19 BlackRock, Inc. 0.00% 111,000 $876K
20 Goldman Sachs Group Inc 0.00% 15,229 $120K
21 Citadel Advisors LLC 0.00% 10,504 $83K
22 Susquehanna International Group, LLP 0.00% 11,100 $88K
23 Morgan Stanley 0.00% 12,138 $96K
24 Jpmorgan Chase & Co 0.00% 3,636 $28K
25 Larson Financial Group LLC 0.00% 5 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Seres Therapeutics Inc (MCRB)

What does the Smart Money Trend signal show for MCRB?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added MCRB than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MCRB?

More sellers than buyers — 47% buying: Last quarter: 18 funds reduced or exited vs 16 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for MCRB holders?

Smaller funds dominant — 16% AUM from top-100: 17 of 35 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MCRB?

Mostly new holders — 40% entered in last year: Only 2 funds (6%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Seres Therapeutics Inc (MCRB) following the 2026 Q2 hedge fund 13F filings?

As of today, MCRB has moved +9.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.5% for the XLV sector ETF — an outperformance of +6.5%. Since the quarter end (June 30, 2026), MCRB has gained -37.3% vs +8.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →